UK markets close in 7 hours 10 minutes

Clinuvel Pharmaceuticals Limited (CUV.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
14.99+0.10 (+0.67%)
At close: 04:10PM AEST
Currency in AUD

Valuation measures4

Market cap (intra-day) 751.41M
Enterprise value 578.03M
Trailing P/E 26.16
Forward P/E 18.21
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.76
Price/book (mrq)4.21
Enterprise value/revenue 7.12
Enterprise value/EBITDA 11.40

Trading information

Stock price history

Beta (5Y monthly) 0.74
52-week change 3-25.53%
S&P500 52-week change 322.64%
52-week high 321.53
52-week low 312.96
50-day moving average 314.62
200-day moving average 316.22

Share statistics

Avg vol (3-month) 3141.14k
Avg vol (10-day) 3107.54k
Shares outstanding 550.13M
Implied shares outstanding 650.13M
Float 839.5M
% held by insiders 120.44%
% held by institutions 18.94%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.05
Forward annual dividend yield 40.33%
Trailing annual dividend rate 30.05
Trailing annual dividend yield 30.34%
5-year average dividend yield 40.15
Payout ratio 48.73%
Dividend date 3N/A
Ex-dividend date 405 Sept 2023
Last split factor 21:10
Last split date 312 Nov 2010

Financial highlights

Fiscal year

Fiscal year ends 30 Jun 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 36.88%
Operating margin (ttm)42.37%

Management effectiveness

Return on assets (ttm)14.71%
Return on equity (ttm)18.98%

Income statement

Revenue (ttm)81.76M
Revenue per share (ttm)1.65
Quarterly revenue growth (yoy)11.70%
Gross profit (ttm)N/A
EBITDA 44.36M
Net income avi to common (ttm)30.15M
Diluted EPS (ttm)0.57
Quarterly earnings growth (yoy)-4.00%

Balance sheet

Total cash (mrq)174.45M
Total cash per share (mrq)3.52
Total debt (mrq)1.07M
Total debt/equity (mrq)0.60%
Current ratio (mrq)6.86
Book value per share (mrq)3.61

Cash flow statement

Operating cash flow (ttm)42.27M
Levered free cash flow (ttm)31.29M